X

Trial Profile

A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BR115 for Injection in Patients With Advanced Solid Malignancies

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BR 115 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors BioRay Pharmaceutical

Most Recent Events

07 May 2024 New trial record
06 May 2024 According to a Zhejiang Borui Biopharmaceutical Co media release, company received a drug clinical trial approval notice issued by the National Medical Products Administration and will conduct clinical trials for HER2-positive solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com